Further to the announcements by Exor (“Exor” or the “Company”) on 12 August and 12 September, the Company hereby announces that the delisting of its ordinary shares (ISIN NL0012059018) from Euronext Milan is effective as of the date hereof, as determined by Borsa Italiana on 12 August.

Starting from the date hereof, Exor’s ordinary shares will continue to be listed solely on Euronext Amsterdam.

Further to the announcement by Exor (“Exor” or the “Company”) on 12 August, the Company hereby reminds, pursuant to article 2.5.5 of the Rules of the Markets organised and managed by Borsa Italiana S.p.A. (Regolamento dei Mercati organizzati e gestiti da Borsa Italiana S.p.A.), that the delisting of its ordinary shares (ISIN NL0012059018) from Euronext Milan will come into effect on 27 September 2022 (the “Date of Delisting”), as arranged by Borsa Italiana on 12 August.

The Exor Board of Directors’ meeting approved today the 2022 First Half-year Report.

NET ASSET VALUE (NAV)

At 30 June 2022 Exor’s NAV is €25,505 million compared to €31,069 million at 31 December 2021. At 30 June 2022 Exor’s NAV per share amounts to €109.41 compared to €132.41 at 31 December 2021, a decrease of €23.00/share or 17.4%. This compares to a decrease of 14.3% for the MSCI World Index in Euro.

Further to the announcement by Exor (“Exor” or the “Company”) earlier today in respect of the admission of its ordinary shares (ISIN NL0012059018) on Euronext Amsterdam, the Company hereby announces that Borsa Italiana S.p.A. (“Borsa Italiana”), pursuant to articles 2.5.5 and 2.5.6 of the Rules of the Markets organised and managed by Borsa Italiana (Regolamento dei Mercati organizzati e gestiti da Borsa Italiana S.p.A.), has arranged for the delisting of Exor’s ordinary shares from Euronext Milan, with effect from 27 September 2022 (the “Date of Delisting”).

As announced by Exor (“Exor” or the “Company”) on 3 August 2022, the Euronext Listing Board has approved the admission to listing and trading of the Company’s ordinary shares (ISIN NL0012059018) on Euronext Amsterdam, a regulated market organized and managed by Euronext Amsterdam N.V., which hosts some of Europe’s leading corporations, and as further announced by Exor on 5 August 2022, the Dutch Authority for the Financial Markets (the AFM) has approved the prospectus relating to the admission to listing and trading of the Company’s ordinary shares on Euronext Amsterdam.

As announced by Exor (“Exor” or the “Company”) on 29 July 2022, the Company’s board of directors has approved the transfer of the listing of the Company’s ordinary shares (ISIN NL0012059018) to Euronext Amsterdam, a regulated market organised and managed by Euronext Amsterdam N.V., which hosts some of Europe’s leading corporations, and as announced by Exor on 3 August 2022, the Company has received approval by the Euronext Listing Board of the admission to listing and trading of the Company’s ordinary shares on Euronext Amsterdam.

As announced by Exor (“Exor” or the “Company”) on 29 July 2022, the Company’s board of directors has approved the transfer of the listing of the Company’s ordinary shares (ISIN NL0012059018) to Euronext Amsterdam, a regulated market organised and managed by Euronext Amsterdam N.V., which hosts some of Europe’s leading corporations.

SHARE BUYBACK TO CONTINUE WITH A SECOND TRANCHE OF UP TO €250 M

Exor (“Exor” or the “Company”) announces that its Board of Directors approved today the transfer of the listing of the Company’s ordinary shares (ISIN NL0012059018) to Euronext Amsterdam, which hosts some of Europe’s leading corporations.

Exor N.V. has closed today the agreement to acquire a 10% shareholding of Institut Mérieux, the privately held global healthcare holding of the Mérieux family. A consideration of €278 million, corresponding to one third of the €833 million total investment, was paid today by way of a reserved capital increase, while the remaining amount is expected to be contributed within the next 12 months.

As part of the partnership sealed with the Mérieux family, John Elkann and Benoît Ribadeau-Dumas have joined Institut Mérieux’s Board of Directors.